Leica Biosystems, Indica Labs partner with Lunit. May 29, 2026 - Leica Biosystems, Indica Labs, and Lunit are partnering to develop AI-powered image analysis algorithms. The collaboration will focus on PD-L1 and emerging immunohistochemistry biomarkers and brings together Leica Biosystems' PD-L1 IHC assay platform, Aperio GT 450 digital pathology scanner, Aperio Halo AP image management solution, and Lunit Scope biomarker scoring algorithm to deliver an AI-powered pathology workflow. The companies say the integrated workflow will support pharmaceutical partners conducting clinical research. "By combining Leica Biosystems' expertise in IHC staining and digital pathology, Indica Labs' image management platform, and Lunit's advanced AI analysis, the partnership aims to support consistent scoring approaches, enable robust biomarker analysis, and accelerate research," according to a joint press statement from the companies. The first product is an AI-powered Lunit Scope algorithm designed for Leica Biosystems' PD-L1 primary antibody (CAL10). The new algorithm, Lunit Scope PD-L1 CAL10 NSCLC, is for research use only and available now through Leica Biosystems' Aperio AI Store.

Industry leaders Leica Biosystems, Indica Labs and Lunit partner to develop ai-powered computational pathology Assays for PD-L1 and emerging biomarkers. Building on the market-defining computational pathology partnership between Leica Biosystems and Indica Labs, this new collaboration integrates Lunit's advanced AI capabilities into the best-in-class IHC staining and digital pathology ecosystem. VISTA, California, ALBUQUERQUE, New Mexico, and SEOUL, South Korea - May 26, 2026 - Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Indica Labs, a global leader in AI-powered digital pathology software, today announced a strategic collaboration with Lunit (KRX:328130.KQ), a leading provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms. The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems' PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC[1], is now available through Leica Biosystems' Aperio AI Store. In driving this collaboration, Leica Biosystems will work together with Indica Labs and Lunit to support pharmaceutical partners in integrating AI-enabled digital pathology into routine clinical research. Today, biomarker scoring remains highly variable, as disease state assessments and treatment decisions often rely on manual evaluation of stained tissue under a microscope. This process can be time-consuming and prone to human variability. By combining Leica Biosystems' expertise in IHC staining and digital pathology, Indica Labs' image management platform, and Lunit's advanced AI analysis, the partnership aims to support consistent scoring approaches, enable robust biomarker analysis, and accelerate research workflows. The partnership brings together Leica Biosystems' PD-L1 IHC assay platform[1], Aperio GT 450 digital pathology scanner[1], Aperio HALO AP image management solution[2], and now Lunit SCOPE biomarker scoring algorithm[1] to deliver a seamless, AI-powered pathology workflow. "As a first step, we're integrating Lunit's algorithm directly into our image management software powered by Indica Labs, which enables a continuous workflow for users of the Aperio GT 450 scanner," said Karan Arora, SVP of Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. "This launch aligns with our long-term vision to deliver scalable, seamlessly integrated research workflows to the market." This three-way integration reflects a shared commitment to open pathology and interoperability. Indica Labs CEO Steven Hashagen emphasized that "robust end-to-end solutions like these are a critical step toward realizing the promise of AI in digital pathology." Brandon Suh, CEO of Lunit, added, "We are encouraged by the strong interest from pharmaceutical partners and excited about the potential this collaboration holds. Together, we're applying AI to pathology image analysis at unprecedented scale, with a shared goal of delivering precision diagnostics that translate into tangible improvements in patient care." [1] For research use only. Not for use in diagnostic procedures. [2] Aperio HALO AP(R) is CE-IVDR marked for in vitro diagnostic use in Europe, the UK, and Switzerland. Aperio HALO AP(R) is for research use only in the US and is not FDA cleared for clinical diagnostic use. About Leica Biosystems Leica Biosystems is a cancer diagnostics company and a global leader in end-to-end anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company's mission of 'Advancing Cancer Diagnostics, Improving Lives' is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. Learn more at www.leicabiosystems.com. About Indica Labs Indica Labs is the global leader in AI-powered digital pathology software and services. Its flagship HALO and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, Indica Labs Inc. help pharma companies, diagnostic labs, hospitals, research organizations, and Indica's own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery. About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 6,500 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals - including The Lancet Digital Health and Journal of Clinical Oncology - and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io. About Danaher Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through its connected ecosystem of industry-leading businesses, Indica Labs Inc. work side by side with customers to solve their most complex scientific and clinical challenges - helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, its advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, its approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Lunit highlights ai-powered IHC and tumor microenvironment research at ASCO 2026. May 21, 2026 At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. SEOUL, South Korea, May 22, 2026 /PRNewswire/ - Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announces that five studies featuring its AI biomarker platforms are being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, IL. Lunit at ASCO 2026 This year's presentations reflect Lunit's expanding biomarker research beyond conventional immune profiling toward integrated AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment (TME) analysis. Using AI to characterize HER2 expression, immune phenotypes, tertiary lymphoid structures (TLS), tumor-infiltrating lymphocytes (TILs), and endothelial cells, the studies highlight the potential of integrated biomarker analysis to improve precision patient stratification across multiple cancer types. The five presentations include studies across biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC), microsatellite-stable (MSS), metastatic colorectal cancer and advanced gastric cancer (AGC). One of the featured studies, led by researchers at Yonsei University College of Medicine, evaluates a first-line quadruplet regimen consisting of trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive advanced BTC. The study is selected as a Rapid Oral Presentation at ASCO 2026. Using AI-powered whole-slide image (WSI) analysis, researchers analyze HER2 expression and immune phenotypes within tumor tissue. Among 40 patients enrolled in the multi-center phase Ib/II trial, the combination of therapy demonstrates an objective response rate (ORR) of 55%, disease control rate (DCR) of 95%, and median progression-free survival (PFS) of 10.6 months. Patients with HER2 IHC 3+ tumor cell proportions >=10%, as identified by AI analysis, achieve substantially higher response rates compared to those below the threshold (80% vs. 36.4%). The study demonstrates how integrated AI-powered HER2 and spatial tumor microenvironment analysis may help identify patients more likely to benefit from HER2-targeted combination therapies. Another study characterizes the tumor microenvironment landscape of HER2-overexpressing NSCLC using AI-powered spatial analysis. Across more than 2,000 NSCLC whole-slide images, HER2-overexpressing tumors demonstrate significantly reduced tumor-infiltrating lymphocyte density and lower proportions of inflamed immune phenotype compared to non-overexpressing tumors. The immune-cold phenotype becomes more pronounced in tumors with higher proportions of HER2 3+ cells. The study provides additional insight into the biological relationship between HER2 overexpression and tumor immune status, while highlighting the broader potential of combining AI-powered HER2 analysis with spatial tumor microenvironment characterization in biomarker research. Another featured study, conducted with Seoul National University Hospital, explores AI-powered spatial tumor microenvironment analysis in adenoid cystic carcinoma (ACC), a rare cancer with limited treatment options. Researchers identify a subgroup of ACC patients with high endothelial cell and tumor-infiltrating lymphocyte (TIL) densities who demonstrate significantly prolonged progression-free survival following axitinib treatment (19.6 months vs. 11.1 months). The findings suggest that AI-based spatial profiling may help distinguish responder populations that are difficult to stratify using conventional biomarkers alone. Researchers at Asan Medical Center investigate AI-powered tumor microenvironment analysis in MSS metastatic colorectal cancer, which is generally considered resistant to immune checkpoint inhibitors (ICIs). Researchers find that patients with larger tertiary lymphoid structure (TLS) regions identified by AI demonstrate improved progression-free survival and overall survival following immunotherapy. The findings highlight the potential of AI-powered spatial analysis to identify MSS colorectal cancer patients more likely to benefit from immunotherapy. "These studies demonstrate how AI-powered biomarker analysis is evolving beyond conventional immune profiling toward integrated HER2/IHC quantification and spatial tumor microenvironment analysis," said Brandon Suh, CEO of Lunit. "We believe integrated biomarker analysis will play an increasingly important role in precision oncology research, patient stratification, and treatment-response assessment." Lunit will be exhibiting at ASCO 2026, where attendees can learn more about the company's AI biomarker platforms and research collaborations. Lunit's featured AI biomarker studies at ASCO 2026 include: About Lunit Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Its clinically validated solutions span medical imaging, breast health, and biomarker analysis - empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum. Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Its FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development. Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact - for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.